Yu-Chen Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yu-Chen Liu has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Cai Yi Wang
School of Pharmacy, Hangzhou Medical College, Hangzhou, 311399, Zhejiang, China.
1 shared publication - Chunxiao Zong
College of Life Science, Zhejiang Chinese Medical University, Hangzhou 310053, China
1 shared publication - Fang-Xin Wang
Guangxi Normal University 15 Yu Cai Road
1 shared publication - Gang Wei
College of Intelligent Metallurgy Guangxi Modern Polytechnic College, Hechi, Guangxi, China
1 shared publication - Heng-Shan Wang
Key Laboratory for Chemistry and Molecular Engineering of Medicinal Resources (Ministry of Education of China), Guangxi Key Laboratory of Chemistry and Molecular Engineering of Medicinal Resources, University Engineering Research Center for Chemistry of Characteristic Medicinal Resources (Guangxi), Guangxi Normal University, 541004, China
1 shared publication - Jiannan Qiu
School of Life Sciences, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, 310053, PR China; Zhejiang-Hong Kong Joint Laboratory of Liver and Spleen Simultaneous Treatment in Traditional Chinese Medicine, Hangzhou, Zhejiang, 310053, PR China; Lipid Metabolism Laboratory, Key Laboratory of State Administration of Traditional Chinese Medicine, Hangzhou, Zhejiang, 310053, PR China; Institute of Lipid Metabolism Zhejiang Chinese Medical University, Hangzhou, Zhejiang, 310053, PR China
1 shared publication
Latest Publications
- Open Access
Design and Synthesis of Novel Indole Ethylamine Derivatives as a Lipid Metabolism Regulator Targeting PPARα/CPT1 in AML12 Cells
Peroxisome proliferator-activated receptor alpha (PPARα) and carnitine palmitoyltransferase 1 (CPT1) are important targets of lipid metabolism regulation for nonalcoholic fatty liver disease (NAFLD) therapy. In the present study, a set of novel indole ethylamine derivatives (4, 5, 8, 9) were designed and synthesized. The target product (compound 9) can effectively activate PPARα and CPT1a. Consistently, in vitro assays demonstrated its impact on the lipid accumulation of oleic acid (OA)-induced AML12 cells. Compared with AML12 cells treated only with OA, supplementation with 5, 10, and 20 μM of compound 9 reduced the levels of intracellular triglyceride (by 28.07%, 37.55%, and 51.33%) with greater inhibitory activity relative to the commercial PPARα agonist fenofibrate. Moreover, the compound 9 supplementations upregulated the expression of hormone-sensitive triglyceride lipase (HSL) and adipose triglyceride lipase (ATGL) and upregulated the phosphorylation of acetyl-CoA carboxylase (ACC) related to fatty acid oxidation and lipogenesis. This dual-target compound with lipid metabolism regulatory efficacy may represent a promising type of drug lead for NAFLD therapy.
Open AccessDesign and Synthesis of Novel Indole Ethylamine Derivatives as a Lipid Metabolism Regulator Targeting PPARα/CPT1 in AML12 Cells
Peroxisome proliferator-activated receptor alpha (PPARα) and carnitine palmitoyltransferase 1 (CPT1) are important targets of lipid metabolism regulation for nonalcoholic fatty liver disease (NAFLD) therapy. In the present study, a set of novel indole ethylamine derivatives (4, 5, 8, 9) were designed and synthesized. The target product (compound 9) can effectively activate PPARα and CPT1a. Consistently, in vitro assays demonstrated its impact on the lipid accumulation of oleic acid (OA)-induced AML12 cells. Compared with AML12 cells treated only with OA, supplementation with 5, 10, and 20 μM of compound 9 reduced the levels of intracellular triglyceride (by 28.07%, 37.55%, and 51.33%) with greater inhibitory activity relative to the commercial PPARα agonist fenofibrate. Moreover, the compound 9 supplementations upregulated the expression of hormone-sensitive triglyceride lipase (HSL) and adipose triglyceride lipase (ATGL) and upregulated the phosphorylation of acetyl-CoA carboxylase (ACC) related to fatty acid oxidation and lipogenesis. This dual-target compound with lipid metabolism regulatory efficacy may represent a promising type of drug lead for NAFLD therapy.